Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
FOR IMMEDIATE RELEASE July 2007 Ichor Medical Systems Leadership Founded in 1994, Ichor has developed the only fully integrated push button electroporation device that allows effective, consistent and reproducible administration of DNA from patient to patient with minimal operator training or skill. The automated Ichor TriGrid™ Delivery System (TriGrid) enables total control of the site of injection, placement of electrodes, rate of agent administration, and timing of electroporation delivery. As a result, TriGrid makes the clinical application of electroporation easy, safe and effective, with DNA uptake enhanced by several orders of magnitude compared to conventional methods of delivery. The development of the TriGrid and its rapidly expanding use in a wide range of preclinical and clinical studies around the world is being led by a management team with unequalled experience and expertise. The team includes: Robert Bernard, President & CEO Bob co-founded Ichor and led the team that invented the TriGrid platform technology and established its proof of concept. Throughout his business and professional career, he has developed an extensive background in the life sciences. He is a proven entrepreneur with experience managing and directing innovative technology-based companies. Prior to founding Ichor, he was president and founder of Bernard Foods, Inc., an innovative, technology-based food business that was acquired by Nestle in 1992. Bob served as Nestle vice president, new business development until founding Ichor. Bob received his degree in Mechanical and Electrical Engineering from Louisiana State University. Drew Hannaman, Vice President, Research and Development Drew joined Ichor in 1995 after he earned his B.S. in Bioengineering/Cybernetics at the University of California, Los Angeles. He is a co-inventor of Ichor's TriGrid technology and designed and developed the company's experimental and clinical administration systems. He leads the multi-disciplinary team responsible for Ichor's DNA drug research, development, regulatory, and manufacturing activities and manages Ichor's collaborations and partnerships. Drew speaks at industry conferences on the future of electroporation for both prophylactic and therapeutic applications. Ichor – Management Team Page 2 of 3 Alain Luxembourg, M.D., Ph.D., Director, Infectious Disease Programs Alain joined Ichor as a Senior Research Scientist in 2001. He received his M.D. with a specialty in Public Health at the University of Montpellier, France and his Ph.D. in Immunology at the University of Aix-Marseille, France. Prior to joining Ichor, he was a Research Scientist at La Jolla Institute for Allergy and Immunology conducting studies on antigen recognition and lymphocyte activation. He completed his post-doctoral work in Immunology at The Scripps Research Institute and the R.W. Johnson Pharmaceutical Research Institute. Alain has played a leading role in the development of the vaccine program at Ichor. He is currently principal investigator on several Ichor vaccine and immunotherapy projects through the NIH SBIR program and contracts from the DoD as well as with outside partners. Claire Evans, Ph.D., Director, Protein Therapeutics Claire joined Ichor as a Senior Research Scientist in 2003. Prior to this, she directed gene expression profiling programs at Digital Gene Technologies in the areas of multiple sclerosis, infectious diseases, and mucosal vaccines. Formerly, she was an Assistant Professor at The Scripps Research Institute in the Department of Neuropharmacology where she ran research programs in central nervous system inflammation and demyelination, autoimmunity, and persistent viral infections. She has been a co-editor of the journal, CNS & Neurological Disorders - Drug Targets (formerly Current Drug Targets - CNS and Neurological Disorders), since 2002. Claire received her Ph.D. in Biological Chemistry at the University of Michigan, Ann Arbor. She is currently principal investigator on several Ichor projects. Karen E. Dolter, Ph.D., Senior Research Scientist Karen joined Ichor in 2005 as a Senior Research Scientist and currently designs, oversees, and interprets in vitro and in vivo experiments, including GLP preclinical safety studies, for developing and analyzing gene delivery and expression methods. She earned her Ph.D. in Microbiology/Immunology from the University of Michigan and her B.A. in Biochemistry-Molecular Biology at the University of California, Santa Barbara. Karen worked in postdoctoral positions at Wayne State University, La Jolla Cancer Research Foundation's Burnham Institute, and The Scripps Research Institute in the areas of molecular virology, tumor cell biology and gene regulation research. Prior to joining Ichor, Karen specialized in oncolytic recombinant herpesviruses as an assay development scientist at MediGene, Inc. and in RNA research as a Staff Scientist at Stratagene. Ken Wills, Ph.D., Senior Research Scientist Ken joined Ichor in late 2005 as a Senior Research Scientist. He received his Ph.D. in Pharmacology from Stanford University followed by post-doctoral research at the La Jolla Cancer Research Foundation (now renamed the Burnham Institute) in San Diego. From there, he joined a small start-up company named Canji, Inc. where he initiated a Ichor – Management Team Page 3 of 3 program designing and constructing recombinant adenoviruses expressing therapeutic genes for treating cancer and other hyperproliferative disorders. After Schering-Plough purchased Canji, Ken remained at the San Diego site, serving as Project Leader for multiple interdepartmental projects focused on both technological advancements and preclinical development of biological therapeutics. At Ichor, Ken leads the design and development efforts in optimizing DNA vectors for clinical use as vaccines, biological therapeutics, and cancer treatments when delivered by Ichor's proprietary TriGrid electroporation system. Van Tsai, M.A., Senior Research Scientist Van joined Ichor in 2006 as a Senior Research Scientist and is responsible for developing immunotherapeutics for oncology using the company’s TriGrid platform. She received her MA from Harvard University in Biology/Immunology, and went on to do her fellowship in the Weizmann Institute in the department of biophysics. Van has held an academic post at UCSD as well as positions in biotech and pharmaceutical companies. At Cytel and Epimmune, Inc., she was awarded patents for identifying novel cytotoxic T cells epitopes in melanomas. As a Senior Scientist at Canji, Inc., a subsidiary of Schering-Plough, Van was responsible for pre-clinical pharmacological studies in oncology and immune-mediated inflammatory diseases. May de las Alas, Ph.D., Business Development May first joined Ichor in 1999. In four years as Research Scientist, May was the Project Leader for the adaptation of Ichor’s electroporation technology for delivery of plasmid DNA into muscle tissue. She earned her B.A. in Biology from Boston University and her Ph.D. in Biomedical Sciences from University of California, San Diego (UCSD). May then spent two years with Invitrogen Corp. as a Senior Technical Support Scientist, after which she returned to Ichor and now heads its business development efforts. Her responsibilities include developing contacts within major pharmaceutical companies, coordinating conference exhibitions, and arranging speaking engagements for senior management. Contacts: Gable PR - 877-251-3888 Tom Gable Cell: (619) 251-3881 [email protected] Erin Koch Cell: (619) 261-0762 [email protected] ###